Prothena Corp Plc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
5analysts covering
FY Revenue (est.)
$83.3Mnext fiscal year
FY EPS (est.)
$0.05next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 9 Nov 2026 |
| Q4 and Full Year 2026 Earnings Release | 18 Feb 2027 |
Monitoring Framework
Key Performance Indicators
Total Cash, Cash Equivalents and Restricted Cash Quarterly330.3M
Total Revenue Quarterly51.1M
Net Income (Loss) Quarterly32.7MTarget: -25000000 to -30000000
Watch Items
- BMS decision on PRX019 advancementTrigger: Decision expected by year-end 2026Action: Monitor for potential $55 million clinical milestone payment from Bristol Myers Squibb.
- Novo Nordisk Phase 3 CLEOPATTRA trial enrollment for coramitug (PRX004)Trigger: Prespecified enrollment criteria metAction: Track progress toward earning the remaining portion of the up to $1.2 billion total eligible milestone payments from Novo Nordisk, following the $50 million clinical milestone payment received in Q1 2026.
- BMS-986446 (PRX005) Phase 2 TargetTau-1 trial completionTrigger: Primary completion expected in 1H 2027Action: Evaluate mid-stage clinical data for early Alzheimer's disease treatment.
Research as of 19 Jun 2026